Longeveron Inc SEC Filings

James Nathaniel Powell, Chief Executive Officer and director of Longeveron Inc. (LGVN), filed an Initial Form 3 reporting beneficial ownership after a 09/04/2025 event. He directly holds 80,446 shares of Class A common stock (including RSUs subject to future vesting) and directly holds a warrant for 44,115 Class A shares exercisable 08/11/2025 and expiring 08/11/2027 at an exercise price of $0.85. The Form 3 was signed by an attorney-in-fact on 10/01/2025.

Longeveron Inc. is offering up to 33,655,871 shares of Class A common stock in an at-the-market offering, assuming sale of 14,078,947 shares at $0.76 per share. Proceeds are intended to fund clinical and regulatory development of its lead stem-cell therapy laromestrocel (Lomecel-B) across hypoplastic left heart syndrome (HLHS), mild Alzheimer’s disease (AD) and pediatric dilated cardiomyopathy (DCM), plus manufacturing, regulatory and general corporate needs. Key clinical milestones include the ELPIS II Phase 2b HLHS trial, now fully enrolled with anticipated top-line results in Q3 2026 and a potential BLA filing in late 2026 if successful; Phase 2a CLEAR MIND in mild AD met its primary safety endpoint and showed nominal significance on a secondary cognitive composite with MRI signals of preserved brain volumes including left hippocampus; FDA approved an IND for pediatric DCM on July 8, 2025 with Phase 2 pivotal plans in H1 2026 subject to financing. The company discontinued its Japan frailty trial in April 2024 but continues Bahamas registries and plans an osteoarthritis registry. Net tangible book value per Class A share was $0.62 as of June 30, 2025 and pro forma values are modestly higher. The prospectus highlights typical biotech risks including need for additional capital, regulatory and clinical uncertainties, potential dilution from outstanding warrants, options and convertible shares, and governance provisions such as a dual-class structure and board authority that may limit shareholder actions.

Lincoln Alternative Strategies LLC reports beneficial ownership of 1,176,470 shares of Longeveron Inc. Class A common stock, representing 6.09% of the class based on 19,312,218 shares outstanding as of August 8, 2025. The filing states Lincoln Alternative has sole voting and dispositive power over these shares and disclaims acquisition for the purpose of changing or influencing control of the issuer.

The statement provides the filer’s Delaware organization and business address in Miami Beach, Florida, and class/CUSIP details for clarity. No transactions, arrangements, or group affiliations are reported in this filing.

Longeveron Inc. reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC disclose shared beneficial ownership equal to 2,143,418 shares of Class A common stock, representing approximately 9.99% of the class as of August 15, 2025. The holdings are issuable upon exercise of Intracoastal Warrant 1 and are subject to blocker provisions that limit exercise to prevent exceeding specified ownership thresholds (9.99% or 4.99% depending on the warrant). The filing specifies no sole voting or dispositive power and that the positions are not held to change or influence control of the issuer.

Lisa Locklear, identified on the Form 4 as Chief Financial Officer and a director of Longeveron Inc. (LGVN), made a direct purchase on 08/11/2025 of 11,766 shares of Class A common stock. Each purchased share was accompanied by two and one-half Class A common warrants, for a total of 29,415 warrants, and the combined purchase price for each share plus accompanying warrants was $0.85. Following the reported transaction, Ms. Locklear directly beneficially owned 250,964 shares of Class A common stock.

The warrants are shown with an exercise/conversion price of $0.85 and an expiration date of 08/11/2027, and the reported holdings and transactions are recorded as direct ownership on the Form 4.

Baluch Khoso, a director of Longeveron Inc. (LGVN), reported an insider purchase on 08/11/2025. The filing shows he acquired 11,766 Class A common shares together with 29,415 Class A common warrants at a combined purchase price of $0.85 per share-plus-warrants package. After the transaction, the report lists 52,516 Class A common shares beneficially owned directly.

The warrants are exercisable immediately and expire on 08/11/2027. The Form 4 was signed by an attorney-in-fact on 08/13/2025.